Lannett Co Inc (LCI) : Traders are bullish on Lannett Co Inc (LCI) as it has outperformed the S&P 500 by a wide margin of 8.56% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 6.53%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 7.1% in the last 1 week, and is up 6.37% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 0.41% and the 50-Day Moving Average is 4.93%.The 200 Day SMA reached 18.83% Lannett Company, Inc. is up 27.66% in the last 3-month period. Year-to-Date the stock performance stands at -18.79%.
Lannett Co Inc (LCI) : Currently there are 4 street experts covering Lannett Co Inc (LCI) stock. The most bullish and bearish price target for the stock is $49 and $32 respectively for the short term. The average price target of all the analysts comes to $41. The estimated standard deviation from the target is $7.07.
For the current week, the company shares have a recommendation consensus of Buy. Lannett Co Inc (NYSE:LCI): The stock opened at $32.07 and touched an intraday high of $32.8 on Friday. During the day, the stock corrected to an intraday low of $32.05, however, the bulls stepped in and pushed the price higher to close in the green at $32.58 with a gain of 0.62% for the day. The total traded volume for the day was 1,200,830. The stock had closed at $32.58 in the previous trading session.
Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Companys products include Levothyroxine Sodium tablets, Digoxin tablets, Butalbital products, Ursodiol capsules and pain management products. Levothyroxine Sodium tablets are produced and marketed with around 12 varying potencies. Digoxin tablets are produced and marketed with approximately two different potencies. It distributes around three products containing Butalbital. Ursodiol capsules are produced and marketed in 300 milligram capsules. The Company offers a range of pain management products, such as Cocaine Topical Solution (C-Topical), Morphine Sulfate Oral Solution, Hydromorphone hydrochloric acid (HCl) tablets and Codeine Sulfate tablets.